tirzepatide diabetes trial on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 Adding tirzepatide to basal insulin

The ones who stop early lose only 8.4 percent of body weight before quitting, and most of it comes back

Many GLP1s provide cardiovascular and renal protection, which is vital in CKD patients

Diabetes 2. typu zkoumn jako perspektivn terapeutick monost pro zlepen glykmie a snen rizika komplikac

In contrast, energy intake in the Vehicle and Baseline conditions matched the nutritional recommendations (Vehicle relative to recommended: d = 31 32 kcal, t 4 = 0.97, p = 0.38

MI and its consequent tissue damage leading to heart failure are mainly responsible for the fatality in patients with T2DM

Best when taken as directed by a qualified healthcare professional